Possible XSCID Treatment MB-207 Granted Orphan Drug Designation
LionFive / Pixabay

Possible XSCID Treatment MB-207 Granted Orphan Drug Designation

  Just last week, biopharmaceutical company Mustang Bio announced Orphan Drug designation for its therapeutic candidate, MB-207. This unique lentiviral gene therapy is designed for previously treated patients with X-linked…

Continue Reading Possible XSCID Treatment MB-207 Granted Orphan Drug Designation
KALYDECO Now the First FDA-Approved CFTR Modulator for Pediatric Patients with Cystic Fibrosis
1041483 / Pixabay

KALYDECO Now the First FDA-Approved CFTR Modulator for Pediatric Patients with Cystic Fibrosis

  On September 25, biotechnology company Vertex Pharmaceuticals Incorporated ("Vertex") announced FDA-approval of KALYDECO (ivacaftor) for pediatric patients with cystic fibrosis (CF). Specifically, KALYDECO can treat infants between 4-6 months…

Continue Reading KALYDECO Now the First FDA-Approved CFTR Modulator for Pediatric Patients with Cystic Fibrosis

The Glut1 Deficiency Foundation’s Child Glut1 Zoom Group

  • Post author:
  • Post category:

Glut1 Virtual Community Gatherings: Children with Glut1 Deficiency Glut1 Pals September 26th, 2020 The Glut1 Deficiency Foundation is not letting the coronavirus/COVID-19 pandemic stop them from continuing in their mission…

Continue Reading The Glut1 Deficiency Foundation’s Child Glut1 Zoom Group
EMA Grants PRIME Designation to CTX001, a Sickle Cell Disease Treatment
source: pixabay.com

EMA Grants PRIME Designation to CTX001, a Sickle Cell Disease Treatment

CRISPR Therapeutics, in combination with Vertex Pharmaceuticals, has recently announced that the European Medicines Agency (EMA) has granted the Priority Medicines (PRIME) designation for their sickle cell disease (SCD) treatment,…

Continue Reading EMA Grants PRIME Designation to CTX001, a Sickle Cell Disease Treatment
Experimental Compound Shows Benefit in Mouse Model of Charcot-Marie-Tooth Disease Type 1A
source: pixabay.com

Experimental Compound Shows Benefit in Mouse Model of Charcot-Marie-Tooth Disease Type 1A

According to a story from Charcot-Marie-Tooth News, an experimental HDAC6 inhibitor called CKD-504 appeared to restore myelination in mouse and cell models of Charcot-Marie-Tooth disease type 1A in a recent…

Continue Reading Experimental Compound Shows Benefit in Mouse Model of Charcot-Marie-Tooth Disease Type 1A
Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years
source: pixabay.com

Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years

  Dr. Richard Furie at New York’s Feinstein Institutes recently interviewed with MedPage Today. Dr. Furie discussed the prognosis for lupus nephritis and belimumab (Benlysta), a recently-tested drug that appears…

Continue Reading Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years